Tariquidar dihydrochloride is used as a potent and specific P-glycoprotein (P-gp) inhibitor to reverse multidrug resistance (MDR) in cancer cells; it enhances the cytotoxicity of various chemotherapeutic agents such as Doxorubicin, Paclitaxel, Etoposide, and Vincristine by increasing their intracellular accumulation; it potentiates the antitumor activity of these drugs in vivo against intrinsically resistant and MDR human tumor xenografts without significantly increasing toxicity.